Brain Waves Can Be Manipulated While We Dream, And It Could Help Treat Dementia

 Will your competent? doctor follow this up for possible treatment of your likely dementia post stroke?

With your elevated chances of dementia post stroke,  your competent? doctor is responsible for preventing that! Have they taken on that responsibility? Or are they DOING NOTHING?

With your chances of getting dementia post stroke you need solutions. YOUR DOCTOR IS RESPONSIBLE FOR PREVENTING THIS!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

 

The latest here:

Brain Waves Can Be Manipulated While We Dream, And It Could Help Treat Dementia

Scientists in the UK have manipulated two prominant types of brain wave while volunteers slept, in an effort to develop better tools to study critical neurological activities.

The waves, referred to as alpha and theta oscillations, are strongly associated with resting and relaxing states, including the Rapid Eye Movement (REM) stage of unconsciousness.

Named for the jerking motion of our eyes while in this stage of sleep, REM coincides with the appearance of our most vivid dreams. The stage is also considered to play an important role in memory consolidation and honing cognition, making any brain wave activity an attractive target for scientists.

"Brain oscillations assist in the working of the brain and how it learns and retains information," says neuroscientist Valeria Jaramillo, from the University of Surrey.

"Brain oscillations during REM sleep have been implicated in memory functions – however, their exact role remains largely unclear."

A process called closed-loop auditory stimulation (CLAS) has been successfully used to enhance or disrupt brain waves in non-REM sleep, precisely targeting the ebb and flow of brain waves via sounds delivered through headphones.

The process had rarely been applied to sleepers outside of this state, so researchers from the University of Surrey tested the method on volunteers to determine if it might also apply to waves produced during REM.

Sounds were used to target different types of oscillations. (Jaramillo et al., SLEEP, 2024)

In tests involving 18 participants, the researchers changed both the speed and strength of the brain waves as measured through electrodes on the skull.

Alpha (around 8 to 12 Hertz) and theta (around 4 to 8 Hertz) oscillations typically flow through the brain's frontal region while we're in a relaxed state, such as when we're dozing or deciding whether to get out of bed to start the day.

In fact, these brain waves are pretty similar whether we're awake or in REM sleep. We know that brain waves, pulses of electrical activity triggered by neurons, help in the healthy functioning of the brain. If we can control them to an extent, that's potentially helpful in making sure the brain is working as it should – and in slowing the rate of degeneration associated with dementia.

"Using sound stimulation to change brain oscillations whilst a person sleeps shows therapeutic promise," says University of Surrey neuroscientist Ines Violante.

"There is currently no cure for dementia, only medication that can slow down disease progression or temporarily help a person with their symptoms, so it is important that we think innovatively to develop new treatment options."

A lot more research will be needed to show this can actually have a therapeutic effect on dementia, but scientists have already shown that the symptoms of dementia – trouble with memory and cognitive abilities – often coincide with the slowing of brain wave oscillations, which is something we might now be able to influence.

"This could pave the way for a new approach on how to treat patients with dementia, as the technique is non-invasive and undertaken whilst they are asleep, lessening the disruption to their lives and enabling us to be more targeted in our approach," says Derk-Jan Dijk, a professor of sleep and physiology at the University of Surrey.

The research has been published in SLEEP.

Patient recruitment underway in phase 2a trial for cannabis oil dementia treatment

 With your elevated risk of dementia post stroke, if your doctor isn't closely following this research you don't have a functioning stroke doctor or hospital. Don't do anything with this until your doctor oks it.

Your risk of dementia, has your doctor told you of this?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

What is your doctor's EXACT PROTOCOL TO PREVENT DEMENTIA?

The latest here:

Patient recruitment underway in phase 2a trial for cannabis oil dementia treatment 

MediCane Health Inc. announced recruitment of the first patient for its phase 2a study designed to assess the effects of cannabis oil in adults with probable Alzheimer’s disease who have limited or no response to antipsychotic medication.

According to a company release, the trial is being conducted in two leading academic hospitals in Israel — Sheba Medical Center and Sourasky Medical Center. The trial will include 55 participants, who will receive MediCane’s balanced THC:CBD orally administered cannabis oil extracted from MediCane’s proprietary strain and formulated for blinding purposes, in addition to standard care.

MediCane Health Inc. will soon commence a phase 2a clinical trial to test its proprietary oral medical cannabis oil on patients with behavioral and psychological symptoms of dementia. Source: Adobe Stock.

The first part of the study is an open-label phase that will enroll 15 participants for safety and dose-range finding, followed by a randomized, double-blind, placebo-controlled second phase that will include 40 participants to evaluate safety and efficacy, the company stated.

According to the release, agitation and disruptive behaviors, expressed as excessive fidgeting, restlessness, pacing, shouting, screaming, uninhibited behaviors and aggression, are present in over half of patients with dementia at some point during the illness.

“MediCane is proud to collaborate with two of the leading medical centers in Israel in our journey to find a safe and effective cannabis-based medicine for [behavioral and psychological symptoms of dementia] symptom relief,” Nurit Tweezer-Zaks, MD, MBA, CEO of MediCane research and development, said in the release. “Through this joint effort we hope to be able to successfully complete the study during 2024 and launch the product in Israel, Germany and additional EU markets.”

New research published in the Journal of Alzheimer’s disease has added to the claims that cannabis, or especially the ingredient CBD, might help slow, stop or even reverse dementia in mice.

 New research published in the Journal of Alzheimer’s disease has added to the claims that cannabis, or especially the ingredient CBD, might help slow, stop or even reverse dementia in mice.

Don't do this because this is not human research. Human research will never occur because we have absolute idiots in the federal legislature keeping marijuana as a Schedule I drug with no chance it is having any good use at all while classified as that.

If it seems to come to that I will be toking daily, living in a legal marijuana state, Michigan, is great. 

The article here:

Opinion: The age of the ‘silver stoners’ is nigh

If you were thinking about spending your final years high as a kite—because, let’s face it, why not?—here’s a promising bit of news.

You might be well advised to do so—on doctor’s orders.

New research published in the Journal of Alzheimer’s disease has added to the claims that cannabis, or especially the ingredient CBD, might help slow, stop or even reverse dementia.

Just a two-week course of CBD improved the symptoms and slowed the cognitive decline in laboratory mice with dementia, reported researchers at the medical and dental colleges of Augusta University in Augusta,Ga. The CBD improved the amount of two key proteins in their brains by about 600% and 900%, the university says.

This isn’t the first scientific study suggesting cannabis might help fight dementia. Through 2019, a review of multiple other studies found data pointing the same way.To be sure, when it comes to treating Alzheimer’s, there’s mostly uncertainty. The experts warn that nothing has been “proven” and everything is speculative.

The Alzheimer’s Association warns that cannabis and cannabis-derived products “are not approved…for the treatment or management of Alzheimer’s or other dementia” by the U.S. government. The Food & Drug Administration has already gone after CBD companies for marketing their products as a treatment for Alzheimer’s.

But telling people with a terminal illness not to try a treatment because it might not work is like telling a man who’s just fallen out of an airplane not to pull on the ripcord because, after all, you can’t be certain the parachute will open.

It shows an ignorance of basic game theory, or indeed logic.

 

Focused Transcranial Ultrasound for Treatment of Neurodegenerative Dementia

For our very likely descent into dementia, would this clearing be a preventative task our doctors should be doing? We'll never know since our doctors and hospital will never take responsibility for finding that answer. You're screwed because of incompetence.  

Your chances of getting dementia.

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018

Focused Transcranial Ultrasound for Treatment of Neurodegenerative Dementia

One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?

Ask your doctor and stroke hospital to followup and see how close to regular use this is. Survivors should be able to benefit. 

One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?

By Carl Zimmer

• April 2, 2019

In 2011, Dr. Dena Dubal was hired by the University of California, San Francisco, as an assistant professor of neurology. She set up a new lab with one chief goal: to understand a mysterious hormone called Klotho.

Dr. Dubal wondered if it might be the key to finding effective treatments for dementia and other disorders of the aging brain. At the time, scientists only knew enough about Klotho to be fascinated by it.

Mice bred to make extra Klotho lived 30 percent longer, for instance. But scientists also had found Klotho in the brain, and so Dr. Dubal launched experiments to see whether it had any effect on how mice learn and remember.

The results were startling. In one study, she and her colleagues found that extra Klotho protects mice with symptoms of Alzheimer’s disease from cognitive decline. “Their thinking, in every way that we could measure them, was preserved,” said Dr. Dubal.

Advertisement

She and her colleagues also bred healthy mice to make extra Klotho. They did better than their fellow rodents on learning mazes and other cognitive tests.

Klotho didn’t just protect their brains, the researchers concluded — it enhanced them. Experiments on more mice turned up similar results.

“I just couldn’t believe it — was it true, or was it just a false positive?” Dr. Dubal recalled. “But here it is. It enhances of cognition even in a young mouse. It makes them smarter.”

[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]

Five years have passed since Dr. Dubal and her colleagues began publishing these extraordinary results. Other researchers have discovered tantalizing findings of their own, suggesting that Klotho may protect against other neurological disorders, including multiple sclerosis and Parkinson’s disease.

Now Dr. Dubal and other researchers are trying to build treatments based on these results. Either by injecting Klotho into the body or by stimulating the brain to make more of the hormone, they hope to treat diseases like Alzheimer’s.

The researchers developing these treatments readily acknowledge that they may fail. And other Klotho experts think there’s a huge amount of work left to do first to figure out how Klotho affects the brain.

“You’ve got all of this amazing stuff showing a really major impact, but we can’t really explain why,” said Gwendalyn D. King, a neuroscientist at the University of Alabama at Birmingham. “That’s where we’re stuck.”

But what happens if scientists get unstuck? What if a drug that enhances cognition really were possible?

Eric Juengst, the director of the University of North Carolina Center for Bioethics, has been thinking about these questions for two decades — back when such drugs were little more than thought experiments.

We tend to think of drugs that enhance performance — say, sports doping — as bad. Drugs that cure or prevent diseases are good. “The scientific community and the public all draw that line,” said Dr. Juengst.

When it comes to Klotho, there may be no such line. In theory, such a drug might offer both a way to prevent diseases of the brain and to enhance it.

Recent research is giving these questions a sudden urgency, according to Dr. Juengst.

“It’s exciting for someone who’s been doing armchair work on this for a long time to see it happening in the real world,” he said. “But it also makes it all the more pressing that this conversation get started in earnest.”

The rest is behind the NYTimes paywall unless it is one of the free articles you can get. 

Treating Dementia with Coconut Oil

Your doctor will never approve, see this:

A Harvard professor just busted the myth that coconut oil is good for you, calling it 'pure poison'

You are on your own to solve your dementia/Alzheimers problem.

Treating Dementia with Coconut Oil 

DIET VIDEO: Coconut oil for dementia is a health food that some doctors say may help. See good ways to make best use of today's available research. (This video does not contain medical advice. Always ask your doctor before using coconut oil for dementia.)

A Decades-Old Asthma Drug Has Reversed Brain Damage From Dementia in Mice - zileuton

Did your stroke hospital do anything with this earlier one? If not you need to fire the whole staff.  They will do nothing with this new research.

Can An Anti-Asthma Drug Rejuvenate the Brain? Jan. 2016

A Decades-Old Asthma Drug Has Reversed Brain Damage From Dementia in Mice - zileuton 

Scientists have used a mice model to reverse some of the most severe damage done to the brain by dementia - and they did this with a surprisingly old medication typically used for asthma.
The discovery could open up the road for treatments that could restore memory and spatial impairment in people with conditions like Alzheimer's. While a human treatment is still some way off, the research shows one method we could use to retroactively treat the buildup of tau proteins, long thought to be a key factor in dementia.
Key to the improvement was an asthma drug called zileuton (or Zyflo) that's been in use for 22 years. The team from Temple University in Philadelphia is highly optimistic, claiming that their findings could eventually improve the lives of millions of people with dementia.
"We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits," says senior investigator Domenico Praticò.
There's still plenty we don't know about diseases like Alzheimer's, but the evidence points to tangles of tau proteins blocking connections between neurons. Another protein, amyloid precursor protein (APP), is also thought to be involved.
In this study the scientists targeted inflammatory molecules called leukotrienes. Having found that leukotrienes cause damage to nerve cells as dementia develops, the team wanted to try blocking the formation of these molecules.
That's where zileuton came in. It was given to one group of mice engineered to have similar dementia problems to 60-year-old humans with the condition, while another group of mice were given placebos instead.
After 16 weeks, treated mice were performing much better on maze tests than mice who hadn't received zileuton. The treated group was also found to have 90 percent fewer leukotrienes in their brains, and 50 percent fewer tau tangles.
"It's really dramatic what we observed," Praticò told Stacey Burling at The Inquirer. "For the first time, we are showing that we can do something after the disease is established."
In fact, the synapses of the mice given zileuton looked as healthy as normal mice after close analysis. It's almost as if this aspect of the dementia had been completely cleared up.
Before we get too excited, there are some limitations to consider. For example, these mice didn't have any beta-amyloid plaque build ups (caused by APP) in their brains, which are consistently found alongside tau plaques in human brains with dementia.
And while mice are often used in research for their genetic and biological similarity to humans, transferring treatments over from these animals can be difficult. Add to that the limits of our understanding about dementia, and there's still a lot of work to be done.
Nevertheless, the fact that researchers were able to actually reverse some of the damage of dementia after it had taken hold is cause for celebration, because the condition isn't usually diagnosed in humans until the effects have already started.
Another reason for optimism is that zileuton has already been approved as a safe drug, albeit with advisory warnings and potential side effects. But it should make it easier to set up a clinical trial, which the team of scientists wants to do next.
"This is an old drug for a new disease," says Praticò. "The research could soon be translated to the clinic, to human patients with Alzheimer's disease."
The research has been published in Molecular Neurobiology.

Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review

Maybe you'll want this. There is also this article from 2013 but in mice, so if your doctor did no followup you have an incompetent doctor.
7. Wei N., et al. Delayed intranasal delivery ofhypoxic-preconditioned bone marrow mesenchymal stem  cells enhanced cell homing andtherapeutic benefits after ischemic stroke in mice.  Cell Transplantation, 2013. 22(6) p. 977-991.

And this from Dec. 2016:

How to Improve Your Memory, Mood and Energy with Intranasal Insulin

The latest here:

Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review

• Authors
• Authors and affiliations

• Konstantinos Ioannis AvgerinosEmail author
• Grigorios Kalaitzidis
• Antonia Malli
• Dimitrios Kalaitzoglou
• Pavlos Gr. Myserlis
• Vasileios-Arsenios Lioutas

• Konstantinos Ioannis Avgerinos
  • 1
  • 2
  • 5
  Email author
• Grigorios Kalaitzidis
  • 2
  • 5
• Antonia Malli
  • 3
  • 5
• Dimitrios Kalaitzoglou
  • 3
  • 5
• Pavlos Gr. Myserlis
  • 4
  • 5
• Vasileios-Arsenios Lioutas
  • 6

1. 1.251 Hellenic Airforce General HospitalAthensGreece
2. 2.Department of Medicine, Faculty of Health SciencesAristotle University of ThessalonikiThessalonikiGreece
3. 3.Faculty of MedicineNational and Kapodistrian University of AthensAthensGreece
4. 4.401 General Army HospitalAthensGreece
5. 5.Society of Junior DoctorsAthensGreece
6. 6.Department of Neurology, Division of Cerebrovascular Diseases, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Review

First Online: 01 February 2018

• 1 Shares
• 76 Downloads

Abstract

Background and aims

Due to common pathophysiological findings of Alzheimer’s disease (AD) with diabetes mellitus (DM), insulin has been suggested as a possible treatment of AD or mild cognitive impairment (MCI). A safe alternative of IV insulin is intranasal (IN) insulin. The aim of this systematic review is to investigate the effects of IN insulin on cognitive function of patients with either AD or MCI.

Methods

A literature search of the electronic databases Medline, Scopus and CENTRAL was performed to identify RCTs investigating the effect of IN insulin administration on cognitive tasks, in patients with AD or MCI.

Results

Seven studies (293 patients) met our inclusion criteria. Most studies showed that verbal memory and especially story recall was improved after IN insulin administration. Sometimes the effect was restricted for apoe4 (−) patients. Intranasal insulin did not affect other cognitive functions. However, there were some positive results in functional status and daily activity. Data suggested that different insulin types and doses may have different effects on different apoe4 groups. In addition, the effects of treatment on Αβ levels differed from study to study. Finally, IN insulin resulted in minor adverse effects.

Conclusions

Intranasal insulin improved story recall performance of apoe4 (−) patients with AD or MCI. Other cognitive functions were not affected, but there were some positive results in functional status and daily activity. Since IN insulin is a safe intervention, future studies should be conducted with larger doses and after proper selection of patients and insulin types.

New study on elderly mice suggests cannabis could be a good treatment for dementia.

How many decades before your doctor suggests cannabis for its health benefits? NEVER?
I don't care that this was tested in mice, can't your doctor  think outside the box?  Does your doctor think at all? 

New study on elderly mice suggests cannabis could be a good treatment for dementia.

Cannabis reverses the brain ageing process, new research finds.
The study on elderly mice showed that their brains could be regressed to the state of two-month-olds.
They were given a low-dose treatment with a cannabis-active ingredient (THC).
THC could prove to be a good treatment for dementia eventually, the researchers think.
Professor Andreas Zimmer, who led the research, said:

“With increasing age, the quantity of the cannabinoids naturally formed in the brain reduces.
When the activity of the cannabinoid system declines, we find rapid ageing in the brain.
It looked as though the THC treatment turned back the molecular clock.”

The ‘elderly’ mice in the study were actually two-years-old.
Mice normally start to show cognitive deficits at around one-year-old.
However, a four week low-dose course of THC (the active ingredient in cannabis) reversed these cognitive deficits.
Professor Zimmer said:

“The treatment completely reversed the loss of performance in the old animals.”

The next stage is to conduct clinical trials in humans.
The study was published in the journal Nature Medicine (Bilkei-Gorzo et al., 2017).